DSpace Home
→
Fakülteler / Faculties
→
Tıp Fakültesi
→
Temel Tıp Bilimleri / Basic Medical Sciences
→
Makale Koleksiyonu
→
Browsing Makale Koleksiyonu by Author

Browsing Makale Koleksiyonu by Author "Eskiler, GG; Cecener, G; Egeli, U; Tunca, B;"

Now showing items 1-5 of 5

BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2019)

The objective of the present study was to elucidate the effect of BMN 673 (talozoparib) on BRCA1 mutant (HCC1937) and wild-type (MDA-MB-231) triple negative breast cancer (TNBC). The in vitro cytotoxicity results indicated ...
E-Health and Bioengineering Conference

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (IEEE, 2017)

The anti-estrogen tamoxifen (Tam) is the most preferred option for patients with estrogen-receptor (ER)-positive breast cancer. However, multi-drug resistance (MDR) is a considerable clinical problem in the successful ...
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (SPRINGER/PLENUM PUBLISHERS, 2018)

PurposeThe purpose of the study was to produce BMN 673 loaded solid lipid nanoparticles (SLNs) to improve its therapeutic index, to minimize toxicity and to overcome homologous recombination (HR)-mediated resistance.Meth ...
Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2020)

Herein, we investigated efflux pumps-mediated talazoparib-resistance in the treatment of triple-negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib-solid lipid nanoparticles (SLNs) and then explored ...
Triple negative breast cancer: new therapeutic approaches and BRCA status

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2018)

Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great ...